CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Normobaric oxygen therapyWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug403 Hyperbaric oxygen therapy Wiki 1.00

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D045169 Severe Acute Respiratory Syndrome NIH 0.07
D018352 Coronavirus Infections NIH 0.06

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19)

The 2019-20 coronavirus disease, caused by COVID-19, is an ongoing pandemic.So far, no specific treatment has proven efficacy. Recent case series reported the use of Hyperbaric Oxygen Therapy (HBOT) on 5 severe COVID-19 patients who developed respiratory insufficiency. HBOT mechanisms of tissue oxygenation and anti-inflammatory effect may explain these findings. The purpose of the current study is the evaluate the efficacy of HBOT in moderate-severe COVID-19 patients in a randomized controlled manner.

NCT04358926 COVID-19 Desaturation of Blood Device: Hyperbaric oxygen therapy Device: Normobaric oxygen therapy

Primary Outcomes

Description: Oxygenation index of the lungs calculated PaO2 measured in the blood divided by the inhaled FiO2

Measure: PaO2/FiO2

Time: 1 day and 7 days after the last intervention session

Description: Oxygen saturation measured in %

Measure: SpO2

Time: One hour prior to and after every intervention session, 1 day and 7 days after the last intervention session

Description: Early Warning Score (NEWS) calculated by the patient's vitals and condition

Measure: NEWS Score

Time: One hour prior to and after every intervention session, 1 day and 7 days after the last intervention session

Description: blood CRP level

Measure: Inflammation level -CRP

Time: 1 day and 7 days after the last intervention session

Description: erythrocyte sedimentation rate

Measure: Inflammation level - ESR

Time: 1 day and 7 days after the last intervention session

Description: white blood cells number

Measure: white blood cells number

Time: 1 day and 7 days after the last intervention session

Description: blood IL1 level

Measure: Cytokines - IL1

Time: 1 day and 7 days after the last intervention session

Description: blood IL2 level

Measure: Cytokines - IL2

Time: 1 day and 7 days after the last intervention session

Description: blood IL6 level

Measure: Cytokines - IL6

Time: 1 day and 7 days after the last intervention session

Description: blood IL10 level

Measure: Cytokines - IL10

Time: 1 day and 7 days after the last intervention session

Description: blood TNFalpha level

Measure: Cytokines - TNFalpha

Time: 1 day and 7 days after the last intervention session

Description: blood procalcitonin level

Measure: Inflammation level - procalcitonin

Time: 1 day and 7 days after the last intervention session

Description: blood ferritin level

Measure: Inflammation level - ferritin

Time: 1 day and 7 days after the last intervention session

Secondary Outcomes

Description: Patient's reported symptoms including cough, dyspnea, etc.

Measure: Symptoms level

Time: 1 day and 7 days after the last intervention session

Description: Oxygen amount supplied measured in IU

Measure: Average oxygen supply per day

Time: 1 day and 7 days after the last intervention session

Description: Quantitative measurement of viral load in the blood using quantitative RT-PCR

Measure: Viral load

Time: 1 day and 7 days after the last intervention session

Description: Chest xray changes evaluated qualitatively and quantitatively

Measure: Chest Xray changes

Time: 1 day and 7 days after the last intervention session

Description: number of patients who developed SARS-CoV-2 IgG antibodies

Measure: Number of patients with IgG seroconversion

Time: 1 day and 7 days after the last intervention session

Description: number of patients who developed SARS-CoV-2 IgM antibodies

Measure: Number of patients with IgM seroconversion

Time: 1 day and 7 days after the last intervention session

Description: Pulmonary function tests performed bedside

Measure: FEV1/FVC

Time: 1 day and 7 days after the last intervention session

Description: The measured time the patient suffered symptoms until complete recovery

Measure: Time to symptoms recovery

Time: Within 30 days

Description: The number of patients who required invasive ventilation during the trial

Measure: Number of patients who required invasive ventilation

Time: Within 30 days

Description: The measured time until the patient had two negative SARS-CoV-2 PCR

Measure: Time to negative virus PCR

Time: Within 30 days

Description: The number of patients who died

Measure: Mortality rate

Time: Within 30 days

Description: The number of adverse events in each arm

Measure: Number of barotrauma events (safety)

Time: Within 7 days after the last session


No related HPO nodes (Using clinical trials)